allogeneic mesenchymal stromal cells + beta-tricalcium phosphate

This therapeutic combination consists of allogeneic bone marrow-derived mesenchymal stromal cells (MSCs) seeded onto a synthetic biomaterial scaffold, specifically beta-tricalcium phosphate (beta-TCP, commercially known as ChronOS). Developed by the Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda, this advanced therapy medicinal product (ATMP) is designed to treat complex bone injuries, including non-union and delayed union of long bone fractures. The MSCs provide essential osteogenic potential by differentiating into bone-forming osteoblasts and secreting pro-regenerative paracrine factors such as BMP-2 and VEGF, which stimulate local bone formation and angiogenesis. The beta-tricalcium phosphate component serves as an osteoconductive scaffold, providing structural support and a surface for cell attachment and mineral deposition. This approach aims to provide a viable alternative to autologous bone grafting, reducing donor site morbidity while promoting effective fracture healing.

Brand names

ChronOS

Other names

allogeneic mesenchymal stromal cells + biomaterialallogeneic BM-MSCs + ChronOSA-MSC-ChronOSallogeneic bone marrow-derived mesenchymal stromal cells + beta-TCP